-1366x0.jpg)
Following the series of activities to update knowledge about genetic analysis and testing services of GENTIS, the company organized a presentation seminar on the topic " Optimization of the PGT-M assay in preimplantation genetic analysis" at Phu Tho Obstetrics and Pediatrics Hospital on March 16.
The seminar was attended by nearly 20 doctors and nurses from the leadership of the Center for Reproductive Support and Male Studies of the Hospital. In particular, there was the presence of Dr. Doctor Doan Xuan Kien - Director of Center for Reproductive Support, MSc. Dr. Nguyen Thi Mai - Deputy Director of Center for Reproductive Support and doctors, nurses and technicians working at the central laboratory. GENTIS Company is honored to have the participation of Drs. Duong Thi Phuong - GENTIS Product Management Team Leader directly reports on the latest updates on the PGT-M test.
At the beginning of the report, Pharmacist Phuong shared preliminary about genetic analysis test before embryo transfer. In which, the GENTIS Product Management Team Leader focused on reporting on PGT-M to identify monogenic genetic diseases and its applicability to infertile couples with monogenic genetic diseases.
According to world statistics, the prevalence of monogenic diseases accounts for about 3.5-5.9% of the world population (>400 million patients). Some common single-gene diseases such as Thalassemia, spinal muscular atrophy, Duchenne muscular atrophy, hemophilia, etc. have caused dangerous genetic consequences for many generations of families.
With the development of world science, the PGT-M technique was born, helping many couples with single-gene genetic diseases have a chance to have healthy children. PGT-M is a test performed on embryos, to detect inherited diseases caused by pre-defined gene mutations or with a clear family history.
GENTIS is the unit that has deployed PGT-M at many fertility centers across the country and received very good feedback on the quality of implementation. Dr. Phuong shared that the PGT-M test at GENTIS has been performed with more than 30 genetic disease syndromes. Not only are common single-gene diseases detected, but other rare and dangerous genetic diseases are also performed by GENTIS experts such as Wilson's disease, Pompe syndrome, cystic fibrosis, Fabry disease, congenital hearing loss. , congenital hypothyroidism, Smith-Lemli-Opitz syndrome, vitreous bone disease, inherited polycystic kidney ...
From there, Dr. Duong Thi Phuong emphasized the information that GENTIS successfully optimized the PGT-M test kit including 10 dangerous single-gene diseases, helping to shorten the time to return results from 60 days to only 30 days.
The procedure for performing this test consists of collecting a biopsy embryo or WGA product, along with a reference blood sample from the parents. In some cases, GENTIS may require a third or additional reference sample for the most accurate and clear mutation identification.
In addition to the diseases on the implementation list, the Product Management Team Leader said that GENTIS can perform PGT-M for most diseases and genes, including new diseases that have not yet been implemented in Vietnam. This is one of the great advantages that not all testing units in Vietnam can do.
Besides PGT genetic testing for embryos, parental target gene testing is also an important test for people with a history of genetic diseases or suspected monogenic diseases. Patients will receive counseling and guidance on common monogenic disease screening by GENTIS geneticists.
At that time, the patient can perform the GENTIS 13 hidden genetic disease test package to simultaneously detect mutations in genes related to 13 common genetic diseases in Asians. This is a useful tool to help each individual check whether he or she carries the disease gene or not and assess the possibility of passing the disease gene to children.
At the end of the seminar, doctors at Phu Tho Obstetrics and Pediatrics Hospital had a lively discussion with GENTIS representatives about sample preservation, sample collection as well as the process of performing PGT-M test to detect disease. Thalassemia. According to the Deputy Director of the Center - Mr. Dr. Nguyen Thi Mai, the hospital is currently accepting many patients with problems related to Thalassemia who want to have a healthy baby. The doctor also said that this disease is very dangerous and it is necessary to be screened to limit the birth of sick children and reduce the burden on the family and society.
After an exchange with a representative of Phu Tho Obstetrics and Gynecology Hospital, the GENTIS representative presented the effectiveness of using the PGT-M test in Thalassemia screening and applying it in more than 50 birth reproductive support centers nationwide. GENTIS is committed to implementing rigorous and ISO 9001:2015 PGT-M testing procedures to ensure accurate and reliable results in the shortest possible time.
With the desire to share knowledge about PGT technique and methods to support people with genetic diseases to have healthy children, GENTIS hopes that doctors at Phu Tho Obstetrics and Pediatrics Hospital have had more useful information to advise and consultation with the patient. The company will continue to research on PGT-M on many other rare genetic diseases, increase the success rate for pre-implantation screening and bring happiness to families in Vietnam..
